Masonic Cancer Center, University of Minnesota: all 285 studies

Page 1 of 3. Open to participants first (34), then studies with results posted, then the rest; newest registration first within each.

• GutCheck: Optimization of a Personalized Mobile Health App for Survivors of Gastrointestinal CancerNot yet recruitingNCT07661017Not applicable
• Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCTRecruitingNCT07591649Phase 1/2
• First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 AstrocytomaRecruitingNCT07560865Phase 1
• GTB-5550 in Advanced Solid TumorsRecruitingNCT07541573Phase 1
• MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological DiseasesRecruitingNCT07493538Phase 2
• UNTOLD Ovarian Cancer Unmet Needs SurveyRecruitingNCT07070726
• Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)RecruitingNCT07008638Phase 1/2
• Allo HSCT for High Risk HemoglobinopathiesRecruitingNCT06872333Phase 2
• HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZLRecruitingNCT06792825Phase 2
• Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor MalignanciesNot yet recruitingNCT06772090Not applicable
• Adenovirus (RGDCRAdCOX2F)RecruitingNCT06693986Phase 1
• Trial of Cell Based Therapy for DMDRecruitingNCT06692426Phase 1
• HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AMLRecruitingNCT06594445Phase 1
• Rural Smoking CessationRecruitingNCT06584929Not applicable
• American Indian Smokefree Native RCTRecruitingNCT06544811Not applicable
• Evaluation of Early Identification of Cognitive Side Effects of ImmunotherapyRecruitingNCT06414278
• MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.RecruitingNCT06412497Phase 2
• Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following PancreatoduodenectomyRecruitingNCT06411795Phase 2
• MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin LymphomaRecruitingNCT06377540Phase 2
• Role of Acetaldehyde in the Development of Oral CancerRecruitingNCT05973656Not applicable
• Allo HSCT Using RIC and PTCy for Hematological DiseasesRecruitingNCT05805605Phase 2
• MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme MalignanciesRecruitingNCT05735717Phase 2
• Observational Study of Exposure to Environmental Toxicants Among FirefightersRecruitingNCT05643014
• Study of PAT in Patients With Solid Tumor CancersRecruitingNCT05338658Phase 1
• Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through ExerciseRecruitingNCT05025774
• RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II TrialRecruitingNCT04105270Phase 2
• Adrenoleukodystrophy National Registry StudyRecruitingNCT03789721
• Alpha/Beta TCD HCT in Patients With Inherited BMF DisordersRecruitingNCT03579875Phase 2
• Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersRecruitingNCT03314974Phase 2
• Auto Stem Cell Transplant for Lymphoma PatientsRecruitingNCT03125642Phase 2
• Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk NeuroblastomaRecruitingNCT02605421Phase 2
• Treatment of Graft Failure After Hematopoietic Stem Cell TransplantationRecruitingNCT02161783
• Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)RecruitingNCT01666080Not applicable
• Infusion of Cell Populations From Unlicensed Umbilical Cord Blood UnitsRecruitingNCT01451502Not applicable
• MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerTerminatedNCT05708924Phase 1Results posted
• Assessing the Time Demands of CancerActive, not recruitingNCT05708703Results posted
• App-Assisted Day Reconstruction to Reduce Logistic Toxicity in CancerCompletedNCT05502302Results posted
• QuitGuide for American Indians: Aims 2 & 3CompletedNCT05447156Not applicableResults posted
• HCW9218 in Select Advanced Solid TumorsCompletedNCT05322408Phase 1Results posted
• Sugars in CigarettesCompletedNCT05308316Not applicableResults posted
• PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC TransplantationCompletedNCT05120570Phase 1/2Results posted
• Telehealth-Filter Ventilation ( COMET2P1 )CompletedNCT04969783Not applicableResults posted
• FT538 in Combination With Daratumumab in AML Acute Myeloid LeukemiaCompletedNCT04714372Phase 1Results posted
• FT516 and IL2 With Enoblituzumab for Ovarian CancerCompletedNCT04630769Phase 1Results posted
• FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHLCompletedNCT04555811Phase 1Results posted
• Feasibility of Conducting a Pilot Telehealth Study Assessing the Removal of Filter Ventilation on Smoking Behavior and Biomarkers in Menthol Smokers Switched to Non-menthol CigarettesCompletedNCT04514471Not applicableResults posted
• Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)CompletedNCT04466098Phase 2Results posted
• Metabolism of NNK in Japanese AmericansCompletedNCT04228952Results posted
• A Pilot Feasibility Study of Activated Charcoal in Healthy VolunteersCompletedNCT04204772Early Phase 1Results posted
• Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDSCompletedNCT04055844Phase 2Results posted
• Biomarkers of Exposure and Effect in Standardized Research E-cigarette (SREC) UsersCompletedNCT04003805Phase 1Results posted
• Clinical Trial of Two Study Drinks in Detoxification of Environmental Toxicants and CarcinogensCompletedNCT03978117Phase 2Results posted
• CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and AbirateroneCompletedNCT03934840Phase 2Results posted
• Radiation and Combination Immunotherapy for MelanomaCompletedNCT03850691Phase 2Results posted
• A Study of FMT in Patients With AML Allo HSCT in RecipientsCompletedNCT03678493Phase 2Results posted
• Trial Evaluating MGTA-456 in Patients With High-Risk MalignancyActive, not recruitingNCT03674411Phase 2Results posted
• MT2017-45: CAR-T Cell Therapy for Heme MalignanciesActive, not recruitingNCT03642626Phase 2Results posted
• Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDSCompletedNCT03417154Phase 2Results posted
• BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing CystectomyCompletedNCT03294304Phase 2Results posted
• IP ALT-803 Followed by SQ ALT-803 for Ovarian CancerCompletedNCT03054909Phase 2Results posted
• QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AMLCompletedNCT03050216Phase 2Results posted
• Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme MalignanciesTerminatedNCT02991898Phase 2Results posted
• Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCTCompletedNCT02989844Phase 2Results posted
• Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell TumorsTerminatedNCT02988843Phase 2Results posted
• Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCTCompletedNCT02988466Phase 2Results posted
• UCB Transplant for Hematological Diseases Using a Non Myeloablative PrepCompletedNCT02722668Phase 2Results posted
• Study of Cellutome System for Treatment of Individual Lesions in EB PtsCompletedNCT02670837Not applicableResults posted
• Exemestane in Post-Menopausal Women With NSCLCCompletedNCT02666105Phase 2Results posted
• MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCsCompletedNCT02582775Phase 2Results posted
• Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHDCompletedNCT02525029Phase 1/2Results posted
• MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML PatientsCompletedNCT02395822Phase 2Results posted
• HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or LymphomaCompletedNCT02370160Phase 1/2Results posted
• Negative Pressure Wound Therapy in Obese Gynecologic Oncology PatientsCompletedNCT02309944Not applicableResults posted
• Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic AnemiaCompletedNCT02162420Not applicableResults posted
• Naglazyme After Allo Transplant for Maroteaux-Lamy SyndromeTerminatedNCT02156674Not applicableResults posted
• Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic DiseasesTerminatedNCT02145039Not applicableResults posted
• ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCLCompletedNCT02141451Phase 1/2Results posted
• Prevention of Bone Loss After Pediatric Hematopoietic Cell TransplantationCompletedNCT02074631Phase 2Results posted
• Pilot Study of Multi-Modality Imaging in Patients With Hematologic MalignanciesTerminatedNCT02042924Not applicableResults posted
• IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCTCompletedNCT01885897Phase 1/2Results posted
• Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot StudyCompletedNCT01705288Early Phase 1Results posted
• Busulfan and Cyclophosphamide Followed By ALLO BMTTerminatedNCT01685411Not applicableResults posted
• Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal DisordersCompletedNCT01626092Not applicableResults posted
• Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic SyndromesCompletedNCT01593670Phase 2Results posted
• Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck CancerCompletedNCT01581970Phase 2Results posted
• Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate CancerCompletedNCT01560923Phase 2Results posted
• T-Cell Depleted Double UCB for Refractory AMLTerminatedNCT01464359Phase 2Results posted
• NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid DiseasesCompletedNCT01370213Phase 2Results posted
• Preservation of Ovarian Function After Hematopoietic Cell TransplantTerminatedNCT01343368Phase 2Results posted
• Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)TerminatedNCT01312818Phase 2Results posted
• Influenza Vaccine Post Allogeneic TransplantTerminatedNCT01215981Not applicableResults posted
• Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid MalignanciesCompletedNCT01181258Phase 2Results posted
• Administration of IV Laronidase Post Bone Marrow Transplant in HurlerCompletedNCT01173016Phase 1Results posted
• WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian CancerTerminatedNCT01144442Not applicableResults posted
• Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)TerminatedNCT01106950Phase 2Results posted
• Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast CancerCompletedNCT01105650Phase 2Results posted
• IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic SpreadCompletedNCT01099631Phase 1Results posted
• Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine TherapyTerminatedNCT01056601Phase 2Results posted
• Allogeneic Bone Marrow Transplant for Inherited Metabolic DisordersCompletedNCT01043640Phase 2Results posted
• Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCsCompletedNCT01033552Phase 1/2Results posted

← Masonic Cancer Center, University of Minnesota overview and focus areas